News

HemoShear Develops New Human Tissue-Based Model of Rare Liver Disease Under Research Collaboration with Takeda

Charlottesville, VA – HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has received a milestone payment under its October 2020 research collaboration and service agreement with Takeda. The milestone acknowledges development of a human tissue-based model of an undisclosed rare liver disease using the company’s REVEAL-Tx™ platform. REVEAL-Tx™ combines physiological and computational models of disease to identify novel treatment approaches and select drug candidates in a human-relevant disease context.

In 2021, HemoShear completed a four-year collaboration with Takeda resulting in two novel drug targets for nonalcoholic steatohepatitis (NASH) advancing into Takeda’s Discovery Portfolio.

“I am incredibly proud of our team who went to exhaustive efforts to develop and validate a new rare liver disease model,” said M. Sol Collado, PhD, head of discovery biology. “With this model now available to Takeda and HemoShear scientists, we are initiating an accelerated research plan to assess therapeutic approaches and monitor impact on biomarkers.”

“HemoShear has continued to deliver throughout our liver disease research partnerships,” said Bernard Allan, PhD, head of liver research and drug discovery at Takeda. “We look forward to building on our momentum utilizing HemoShear’s platform and scientific team to help evaluate potential new treatments for a challenging rare liver disease with high unmet need.”

Read more here.

Recent News

11/18/2026

GeneDx Announces Leadership Transition

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that its Board of Directors has appointed Everett Cunningham as Chief Executive Officer and a member of the Board, effective on or before December 15, 2026. Mr. Cunningham succeeds Katherine Stueland, who has announced that …

11/17/2026

LifeNet Health Announced that Rony Thomas has Resigned

LifeNet Health announced that Rony Thomas has resigned as President and Chief Executive Officer and as a member of its Board of Directors, effective November 13, 2026. Mr. Thomas led LifeNet Health since 2004. During his tenure, the organization grew into a global leader in organ and tissue procurement and regenerative medicine. “On behalf of …

11/10/2026

Luminoah Raises $25 Million Series B to Expand Access to Its FDA-Cleared Enteral Feeding System

Luminoah, a medical technology company modernizing enteral nutrition, today announced a $25 million Series B financing led by Sandbox Clinical Ventures, with participation from the Blue Venture Fund, GV (Google Ventures), Sands Capital, Texas Medical Center Venture Fund, the CU Healthcare Innovation Fund, the American Gastroenterological Association GI Opportunity Fund, and existing investors. The Series …